NeoGenomics names new COO

FORT MYERS — Cancer-testing laboratory NeoGenomics named Robert Shovlin its new chief operating officer.

Shovlin, who starts on Oct. 13, most recently served as chief development officer for Bostwick Laboratories, a provider of anatomic-pathology testing services targeting urologists and other clinicians. From 2005 until 2011, he served in progressively more responsible positions, including president and CEO, for Aureon Biosciences, a diagnostics company focused on developing novel and proprietary prostate-cancer tests.

“Rob's strong experience and leadership in the clinical laboratory testing industry, and particularly in anatomic pathology, will be invaluable to us as we expand our business over the next few years, and we are very excited to have Rob join our team,” says Douglas VanOort, chairman and CEO, in a statement.

Mr. Shovlin served as a captain and infantry officer in the U.S. Marine Corps from 1992 until 1997, where he served as a platoon and company commander and as an instructor and staff platoon commander at the Basic School. He holds a Bachelor of Science degree from Pennsylvania State University and an MBA from Rutgers University.

Headquartered in Fort Myers, NeoGenomics has labs in Tampa, Nashville, Tenn., Irvine, Fresno, and West Sacramento, Cal. NeoGenomics provides laboratory services to pathologists, oncologists, urologists and hospitals throughout the country.